Trial Profile
A Phase 2, Single Dose, Open-Label, Exploratory Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Folate-fluorescein isothiocyanate conjugate (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Diagnostic use
- Sponsors On Target Laboratories
- 27 Jan 2020 Results presented in an On Target Laboratories Media Release.
- 27 Jan 2020 According to an On Target Laboratories media release, results were presented at the 56th Annual Meeting of the Society of Thoracic Surgeons (STS), held in New Orleans.
- 19 Aug 2019 According to an On Target Laboratories media release, the top-line data for this study will be available in the first half of 2020.